🔎 Trials Near Me

Home › Multiple System Atrophy › NCT07197866

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

RecruitingPhase 2

An Open-Label Extension, Multi-Centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants With Multiple System Atrophy

Who can join

Ages 30 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* Completion of the treatment period and the week 48(V9) visit of the double-blind trial (TV56286-NDG-20039) whilst remaining compliant with trial requirements
* Females of childbearing potential may be included only if they have a negative pregnancy test at the baseline visit
* Females of childbearing potential whose male partners are potentially fertile (ie, no vasectomy) must use highly effective birth control methods for the duration of the trial and for 28 days after the last does of IMP
* Males who are potentially fertile/reproductively competent (not surgically \[eg, vasectomy\] or congenitally sterile) and their female partners who are of childbearing potential must use, together with their female partners, highly effective birth control methods for the duration of the trial and for 28 days after the last dose of investigational medicinal product

NOTE - Additional criteria apply, please contact the investigator for more information

Exclusion Criteria:

* Is a female participant who is pregnant, plans to become pregnant, or is breastfeeding during the trial
* Is of a vulnerable population (eg, people kept in detention or jail)
* Is using or consuming any prohibited concomitant medications within the specified exclusionary windows of this trial

Note - Additional criteria apply, please contact the investigator for more information

About the study

The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA).

A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286.

The planned total duration of the trial is approximately 100 weeks.

What is being tested

Sponsor: Teva Branded Pharmaceutical Products R&D LLC · Participants: 200 · Started: Sep 30, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT07197866

Locations in the U.S.

CaliforniaTeva Investigational Site 15554, La Jolla
FloridaTeva Investigational Site 15544, Boca Raton
Teva Investigational Site 15555, Tampa
IllinoisTeva Investigational Site 15550, Chicago
KansasTeva Investigational Site 15546, Kansas City
New YorkTeva Investigational Site 15549, New York
Teva Investigational Site 15551, New York
North CarolinaTeva Investigational Site 15553, Durham
PennsylvaniaTeva Investigational Site 15548, Pittsburgh
WashingtonTeva Investigational Site 15543, Spokane

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.